^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    COMETT (Cytosolic Oncogenic Antisense To MET Transcript)

    i
    Other names: COMETT, Cytosolic Oncogenic Antisense To MET Transcript, LINC01510, COMET, Long Intergenic Non-Protein Coding RNA 1510, Correlated-To-MET, NONHSAG048610.2, HSALNG0060759, HSALNG0060755
    Associations

    News

    Trials
    over2years
    Investigating the prognostic role of lncRNAs associated with disulfidptosis-related genes in clear cell renal cell carcinoma. (PubMed, J Gene Med)
    We developed a prognosis predicting model based on 11 selected disulfidptosis-related lncRNAs, the efficacy of which was verified in different cohorts. Furthermore, we delineated an intricate portrait of tumor mutation, immune topography and pharmacosensitivity evaluations within disparate risk stratifications.
    Journal • IO biomarker
    |
    COMETT (Cytosolic Oncogenic Antisense To MET Transcript)
    |
    vinorelbine tartrate • dactinomycin • daporinad (APO866) • vinblastine
    over3years
    Overexpressed LINC01510 Attenuates Epithelial-Mesenchymal Transition in High Glucose-Induced Renal Tubular Epithelial Cells via Inactivating MMP7. (PubMed, Ann Clin Lab Sci)
    Our research shows that LINC01510 overexpression inactivates MMP7 to attenuate high glucose-induced EMT of renal tubular epithelial cells.
    Journal
    |
    CDH1 (Cadherin 1) • FN1 (Fibronectin 1) • VIM (Vimentin) • COMETT (Cytosolic Oncogenic Antisense To MET Transcript) • MMP7 (Matrix metallopeptidase 7)
    |
    CDH1 expression • VIM expression
    almost4years
    Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET. (PubMed, Cancer Res)
    In this study, we identify that loss of an epigenetic factor, lysine methyltransferase 5C (KMT5C), drives resistance of NSCLC to multiple EGFRis, including erlotinib, gefitinib, afatinib, and osimertinib. These findings underscore the loss of KMT5C as a critical event in driving EGFRi resistance by promoting a LINC01510/MET axis, providing mechanistic insights that could help improve NSCLC treatment. Dysregulation of the epigenetic modifier KMT5C can drive MET-mediated EGFRi resistance, implicating KMT5C loss as a putative biomarker of resistance and H4K20 methylation as a potential target in EGFRi-resistant lung cancer.
    Journal
    |
    KMT5C (Lysine Methyltransferase 5C) • COMETT (Cytosolic Oncogenic Antisense To MET Transcript)
    |
    EGFR mutation
    |
    Tagrisso (osimertinib) • erlotinib • Gilotrif (afatinib) • gefitinib